The radioimmunoassay (RIA) method was first developed by S. A. Berson and R. S. Yallow in the late 1950s for the determination of insulin in human serum. Presently, the method is employed extensively to determine numerous hormones, enzymes, and drugs in minute quantities (10-9–10-12 M) in human plasma in order to assess various disease conditions. The general term for this method in both immune and nonimmune systems is the competitive binding assay (CBA).
KeywordsPernicious Anemia Vitro Test Plasma Iron Competitive Binding Assay Free Antigen
Unable to display preview. Download preview PDF.
- Andrews JT, Milne MJ (1977) Nuclear medicine. Wiley, New YorkGoogle Scholar
- Chase GC, Rabinowitz JL (1970) Principles of radioisotope methodology, 3rd edn, Burgess, Minneapolis.Google Scholar
- Hayes RL, Goswitz FA, Pearson Murphy BE (eds) (1972) Radioisotopes in medicine: In vitro studies. CONF-671111, US Atomic Energy Commission, Oak RidgeGoogle Scholar
- Kirkham KD, Hunter WM (1971) Radioimmunoassay methods. Williams & Wilkins, BaltimoreGoogle Scholar
- Moss AJ Jr, Dalrymple GV, Boyd CM (eds) (1976) Practical radioimmunoassay. Mosby, St LouisGoogle Scholar
- Odell WD, Daughaday WH (eds) (1974) Principles of competitive protein-binding assays. Lippincott, PhiladelphiaGoogle Scholar
- Rothfeld B (ed) (1974) Nuclear medicine in vitro. Lippincott, PhiladelphiaGoogle Scholar
- Thorell JI, Larson SM (1978) Radioimmunoassay and related techniques. Mosby, St LouisGoogle Scholar
- Wagner HN (ed) (1968) Principles of nuclear medicine. Saunders, PhiladelphiaGoogle Scholar